74 results about "Obese Mice" patented technology

The invention discloses a diethylstilbestrol compound and application thereof in preparation of a drug for treating osteoporosis and/or hyperlipemia. The structural formula of the diethylstilbestrol compound is shown in the specification. The data of a cellular level pharmacodynamic test show that cajanstilbene H (R is H, and X is Cl) can promote multiplication and osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) of an SD rat. After an ob/ob obese mice orally takes the cajanstilbene H (20 mg/kg/d) continuously for 21 days, the results are as follows: (1) no obvious effect on weight is generated; (2) the bone density of the mice is obviously increased; serum alkaline phosphatase (ALP) and tartrate resistant acid phosphatase (TRACP) level are obviously reduced; and the serum calcium concentration is improved; and (3) levels of total cholesterol (TC), triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) in the serum of the mice are obviously reduced. The results show that the cajanstilbene H has positive significance in treatment of the osteoporosis caused by obesity and high blood sugar, and has a clear curative effect on the aspect of improvement of lipid metabolism of the obese mice. The cajanstilbene H has a clear treatment effect on the osteoporosis caused by obesity and high blood sugar and simultaneously can improve lipid metabolism; and metabasis of hyperlipemia to diabetes mellitus to chronic complication of diabetes mellitus to osteoporosis can be avoided to a certain extent.